Xilio Therapeutics (XLO) Retained Earnings (2020 - 2026)

Xilio Therapeutics has disclosed Retained Earnings across 7 years of filings, most recently posting $507.0 million for Q2 2026.

• In Q2 2026, Retained Earnings rose 20.72% year-over-year to $507.0 million; the TTM figure through Jun 2026 stood at $507.0 million (up 20.72% YoY), while the FY2025 annual figure was $454.1 million, up 13.13% from the prior year.
• Retained Earnings came in at $507.0 million for Q2 2026 at Xilio Therapeutics, up from $500.9 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $507.0 million in Q2 2026 to a low of -$429.1 million in Q3 2025.
• Average Retained Earnings over 5 years is $347.6 million, with a median of $365.4 million recorded in 2023.
• Year-over-year, Retained Earnings surged 349.98% in 2022 and plunged 209.58% in 2025.
• Over 5 years, Retained Earnings stood at $354.8 million in 2022, then increased by 2.14% to $362.3 million in 2023, then increased by 10.77% to $401.4 million in 2024, then gained by 13.13% to $454.1 million in 2025, then advanced by 11.65% to $507.0 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $507.0 million in Q2 2026, $500.9 million in Q1 2026, and $454.1 million in Q4 2025.